A novel approach to the treatment of high-risk non–muscle-invasive bladder cancer: Combining immune checkpoint inhibitor (ICI) and microtubule inhibitor (MTI). This is an ASCO Meeting Abstract from ...

The Decipher Bladder test identifies aggressive bladder cancer, aiding in treatment decisions beyond initial clinical staging. Non-luminal tumors in NMIBC show higher upstaging rates to MIBC and ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary DNA methylation test for bladder cancer diagnosis. Findings indicate that ...

Early detection of bladder cancer can improve clinical outcomes and survival rates, similar to other cancers. One current area of research involves looking at cell mutations in areas where cancer may ...

A urinary DNA methylation test demonstrated high sensitivity and specificity for detecting high-grade or invasive bladder cancer, outperforming both nuclear matrix protein 22 (NMP22) and urine ...

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer. A urine-based test may decrease the number of invasive cystoscopies in ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

Testing for genetic mutations in urine can detect bladder cancer years before the disease shows clinical symptoms, new research has shown. The study, by researchers from France, Iran and the United ...